Close

BIO Submits Comments to HHS Regarding the Proposed Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) Charter

Sep 2 2014
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the proposed changes to the Medicare Evidence Development and Coverage Advisory Committee’s (MEDCAC’s) charter, which were released on August 1, 2014.

BIO Submits Comments to CMS Regarding the End-Stage Renal Disease Prospective Payment System Proposed Rule

Sep 2 2014
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’s) proposed rule regarding payment policies under the End-Stage Renal Disease Prospective Payment published in the Federal Register on July 11, 2014 (the “Proposed Rule”).

BIO Submits Comments to CMS Regarding the CY 2015 Physician Fee Schedule Proposed Rule

Sep 2 2014
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’s) proposed rule regarding payment policies under the physician fee schedule (PFS), clinical laboratory fee schedule, and other revisions to Part B for calendar year (CY) 2015 (the “Proposed Rule”).

BIO Submits Comments to CMS Regarding the CY 2015 Hospital Outpatient Prospective Payment System Proposed Rule

Sep 2 2014
The Biotechnology Industry Organization (BIO) is pleased to comment on the Centers for Medicare & Medicaid Services (CMS) proposed rule regarding payment policies under the calendar year (CY) 2015 hospital outpatient prospective payment system (OPPS), published in the Federal Register on July 14, 2014 (the "Proposed Rule").

BIO Submits Comments on Interim Guidance on cGMP for Compounding Outsourcing Facilities

Sep 1 2014
 The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Current Good Manufacturing Practices—Interim Guidance for Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug and Cosmetic Act.”

BIO submits comments on FDA’s Draft Guidance for Industry: Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biologicals Products

Aug 26 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry on Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products – Recommended Practices (Draft Guidance).

BIO Submits Comments to the EPA on the Agency's Extension of Compliance and Attest Engagement Reporting Deadlines for 2013 RFS

Aug 15 2014
The Biotechnology Industry Organization (BIO) is pleased to have the opportunity today to provide non-adverse comment on the U.S. Environmental Protection Agency’s (EPA) proposed rule: Regulation of Fuels and Fuel Additives: Extension of Compliance and Attest Engagement Reporting Deadlines for 2013 Renewable Fuel Standards1 (hereinafter “proposed rule”).

BIO Submits Comments on Clinical Pharmacology Data to Support Biosimilarity

Aug 11 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product.”

BIO Submits Comments to CMS Regarding its Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed FY 2015 Rates Proposed Rule

Aug 8 2014
June 30, 2014   BY ELECTRONIC DELIVERY   The Honorable Marilyn B. Tavenner Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, DC 20201   Re:  Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2015 Rates; Quality Reporting Requirements for Specific Providers; Reasonable Compensation Equivalents for Physician Services in Excluded Teaching Hospitals; Provider Administrative Appeals and Judicial Review; Enforcement Provisions for Organ Transplant Centers; and Electronic Health Record (EHR) Incentive Program; Proposed Rule [CMS-1607-P]   Dear Administrator Tavenner:   The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS’s) Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2015 Rates Proposed Rule (“the Proposed Rule”), specifically with respect to the Hospital Inpatient Quality Reporting (IQR) Program and the Hospital Value-Based Purchasing (VBP) Program.[1]  BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations.  BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.  [1] 79 Fed. Reg. 27,978 (May 15, 2014).  

BIO Submits Comments on Identification of Suspect Product and Notification

Aug 7 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on the Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification.”